• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    3M Resolves PFAS-Related Claims with the State of New Jersey

    5/12/25 4:15:00 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care
    Get the next $MMM alert in real time by email

    The agreement, which is subject to court approval, includes:

    • A pre-tax present value commitment of approximately $210 million to resolve the legacy Chambers Works litigation and other elements of the settlement.
    • A pre-tax present value commitment of approximately $75 million to resolve current and future statewide claims starting in 2030 and running through 2050.

    ST. PAUL, Minn., May 12, 2025 /PRNewswire/ -- 3M (NYSE:MMM) has reached an agreement that resolves all legacy claims related to the Chambers Works site in Salem County, New Jersey, currently owned by The Chemours Company and, before that, by DuPont. In addition, the settlement extends to PFAS-related claims that the State of New Jersey and its departments have, or may in the future have, against 3M.

    3M (PRNewsfoto/3M)

    This agreement is another important step toward reducing risk and uncertainty on these legacy issues, allowing 3M to focus on its strategic priorities. In 2000, 3M announced it was voluntarily exiting PFOA and PFOS manufacturing and, in 2022, that it would discontinue all PFAS manufacturing by the end of 2025. 3M remains on track to do so.

    In the agreement, the State specifically recognized that 3M "has taken actions, which other companies have not taken, to cease manufacturing" PFAS.

    The company remains focused on creating shareholder value and positioning 3M for success by driving profitable growth, embedding a culture of operational excellence across the enterprise, and advancing our capital allocation priorities. 

    Chambers Works

    This was a case brought by the State of New Jersey seeking damages for contamination emanating from a site owned for decades by DuPont and now owned by The Chemours Company. Multiple contaminants other than PFAS are alleged to be at issue over many years. Historically, 3M supplied PFAS to DuPont at the site but discontinued that supply in 2001.

    Statewide Claims

    While resolving legacy PFAS claims related to the Chambers Works site, 3M also used the opportunity to resolve broader statewide PFAS claims that the State and its departments have, or may in the future have, against 3M. The agreement provides finality and certainty for these claims without further litigation.

    This agreement is not an admission of liability. If the agreement is not approved by the court or certain agreed terms are not fulfilled, 3M is prepared to continue to defend itself in litigation.

    Financial Considerations

    Under the terms of the agreement, 3M has agreed to contribute amounts payable over 25 years. The payment structure provides predictable cash flow with payments aligned to reflect other company obligations.

    3M expects to record a pre-tax charge of approximately $285 million in the second quarter of 2025 and intends to reflect as an adjustment in arriving at results. This pre-tax charge includes:

    • $210 million for the settlement for Chamber Works and other elements of the settlement.
    • $75 million for existing and future PFAS-related claims by the State representing the present value of payments starting in 2030 and running through 2050.

    Additional details will be included in 3M's filings with the Securities and Exchange Commission and on the investor relations website at https://investors.3m.com.

    Forward-Looking Statements

    This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of words such as "plan," "expect," "aim," "believe," "project," "target," "anticipate," "intend," "estimate," "will," "should," "could," "would," "forecast" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Forward-looking information is based on management's estimates, assumptions, and projections, and is subject to significant uncertainties and other factors, many of which are beyond 3M's control. Important risk factors could cause actual future results and other future events to differ materially from those currently estimated by management, including, but not limited to, whether the court approved PWS Settlement will be appealed, the filing of additional, or the outcome of any other pending or future, litigation relating to PFAS or related products or chemistries, costs of remediation obligations relating to PFAS or related products or chemistries, whether the Company's insurance recovery activities will be successful, changes in related laws or regulations, or the impact of the settlement, any litigation or related matters on 3M's financial condition. Additional important risk factors that could cause future actual results or events to differ materially are the following: (1) worldwide economic, political, regulatory, international trade, geopolitical, capital markets and other external conditions and other factors beyond the Company's control, including inflation, recession, military conflicts, natural and other disasters or climate change affecting the operations of the Company or its customers and suppliers; (2) foreign currency exchange rates and fluctuations in those rates; (3) risks related to certain fluorochemicals, including liabilities related to claims, lawsuits, and government regulatory proceedings concerning various PFAS-related products and chemistries, as well as risks related to the Company's plans to exit PFAS manufacturing and discontinue use of PFAS across its product portfolio; (4) legal proceedings, including significant developments that could occur in the legal and regulatory proceedings described in the Company's Annual Report on Form 10-K for the year ended Dec. 31, 2023 and any subsequent quarterly reports on Form 10-Q (the "Reports"); (5) competitive conditions and customer preferences; (6) the timing and market acceptance of new product and service offerings; (7) the availability and cost of purchased components, compounds, raw materials and energy due to shortages, increased demand and wages, supply chain interruptions, or natural or other disasters; (8) unanticipated problems or delays with the phased implementation of a global enterprise resource planning (ERP) system, or security breaches and other disruptions to the Company's information technology infrastructure; (9) the impact of acquisitions, strategic alliances, divestitures, and other strategic events resulting from portfolio management actions and other evolving business strategies; (10) operational execution, including the extent to which the Company can realize the benefits of planned productivity improvements, as well as the impact of organizational restructuring activities; (11) financial market risks that may affect the Company's funding obligations under defined benefit pension and postretirement plans; (12) the Company's credit ratings and its cost of capital; (13) tax-related external conditions, including changes in tax rates, laws or regulations; (14) matters relating to the spin-off of the Company's Health Care business; and (15) matters relating to Combat Arms Earplugs ("CAE"), including those relating to, the August 2023 settlement that is intended to resolve, to the fullest extent possible, all litigation and alleged claims involving the CAE sold or manufactured by the Company's subsidiary Aearo Technologies and certain of its affiliates and/or 3M. Changes in such assumptions or factors could produce significantly different results. A further description of these factors is located in the Reports under "Cautionary Note Concerning Factors That May Affect Future Results" and "Risk Factors" in Part I, Items 1 and 1A (Annual Report) and in Part I, Item 2 and Part II, Item 1A (Quarterly Reports). The Company assumes no obligation to update any forward-looking statements discussed herein as a result of new information or future events or developments.

    About 3M

    3M (NYSE:MMM) believes science helps create a brighter world for everyone. By unlocking the power of people, ideas, and science to reimagine what's possible, our global team uniquely addresses the opportunities and challenges of our customers, communities, and planet. Learn how we're working to improve lives and make what's next at 3M.com/news.

    Please note that the company announces material financial, business and operational information using the 3M investor relations website, SEC filings, press releases, public conference calls and webcasts. The company also uses the 3M News Center and social media to communicate with our customers and the public about the company, products and services and other matters. It is possible that the information 3M posts on the News Center and social media could be deemed to be material information. Therefore, the company encourages investors, the media and others interested in 3M to review the information posted on 3M's news center and the social media channels such as @3M or @3MNews.

    Contacts

    3M

    Investor Contacts:

    Diane Farrow, 612-202-2449

    or

    Eric Herron, 651-233-0043

    Media Contact:

    Allie Fjelstad, [email protected]

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/3m-resolves-pfas-related-claims-with-the-state-of-new-jersey-302452892.html

    SOURCE 3M Company

    Get the next $MMM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MMM

    DatePrice TargetRatingAnalyst
    1/16/2026$182.00Overweight → Neutral
    Analyst
    12/8/2025$178.00Buy → Hold
    Deutsche Bank
    10/22/2025$160.00Underweight → Equal-Weight
    Morgan Stanley
    1/22/2025$140.00 → $170.00Equal Weight → Overweight
    Wells Fargo
    11/13/2024$184.00Neutral → Buy
    UBS
    10/22/2024Hold → Buy
    Melius
    9/6/2024$125.00Underweight
    Morgan Stanley
    7/30/2024$145.00Hold → Buy
    Argus
    More analyst ratings

    $MMM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    January 22, 2021 - Coronavirus (COVID-19) Update: January 22, 2021

    For Immediate Release: January 22, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The FDA’s Office of Criminal Investigations recently investigated a case that has led to an arrest and the filing of a criminal complaint by the U.S. Department of Justice for introducing misbranded drugs into interstate commerce. The criminal investigation found th

    1/22/21 3:54:10 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    $MMM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: EVP, Chief Legal Off & Secret Rhodes Kevin H covered exercise/tax liability with 5,837 shares, decreasing direct ownership by 15% to 32,633 units (SEC Form 4)

    4/A - 3M CO (0000066740) (Issuer)

    2/18/26 4:14:11 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    Amendment: EVP & Chief Info Digital Off Murphy Mark W. covered exercise/tax liability with 4,793 shares, decreasing direct ownership by 27% to 13,025 units (SEC Form 4)

    4/A - 3M CO (0000066740) (Issuer)

    2/18/26 4:12:20 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    Amendment: EVP & Chief HR Officer Dickson Zoe L covered exercise/tax liability with 475 shares, decreasing direct ownership by 3% to 17,666 units (SEC Form 4)

    4/A - 3M CO (0000066740) (Issuer)

    2/18/26 4:10:40 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    $MMM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    3M appoints Meagan Linn as Senior Vice President, Government Affairs

    ST. PAUL, Minn., Feb. 16, 2026 /PRNewswire/ -- 3M today announced the appointment of Meagan Linn as Senior Vice President, Government Affairs. In this role, Linn will oversee the company's engagement with the executive branch, policymakers, regulatory agencies, and industry associations, globally to advance public policy dialogue. She will also be responsible for developing business growth through government contracts. Linn brings 20 years of experience in public policy, with 12 years at Northrop Grumman Corporation, most recently as government policy lead and Chief of Staff, an

    2/16/26 10:00:00 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    3M Announces New Board Appointment

    Neil Mitchill elected to the Board of Directors ST. PAUL, Minn., Feb. 5, 2026 /PRNewswire/ -- 3M (NYSE:MMM) announced today the election of Neil G. Mitchill, Jr. to 3M's Board of Directors, effective Feb. 6, 2026. Mr. Mitchill also has been appointed as a member of the Audit Committee and the Nominating and Governance Committee of the Board. Mr. Mitchill is the Executive Vice President and Chief Financial Officer, RTX Corporation. Holding this position since 2021, his responsibilities span financial reporting and controls, planning and analysis, investor relations, internal audit, tax and treasury. Prior to his current role, Mr. Mitchill served as Corporate Vice President of Financial Planni

    2/5/26 8:30:00 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    3M Board Declares Quarterly Dividend

    ST. PAUL, Minn., Feb. 3, 2026 /PRNewswire/ -- The 3M Company Board of Directors (NYSE:MMM) today declared a dividend on the company's common stock of $0.78 per share for the first quarter of 2026. The dividend is payable March 12, 2026, to shareholders of record at the close of business on Feb. 13, 2026. 3M has paid dividends to its shareholders without interruption for more than 100 years. About 3M 3M (NYSE:MMM) is focused on transforming industries around the world by applying science and creating innovative, customer-focused solutions. Our multi-disciplinary team is working to solve tough customer problems by leveraging diverse technology platforms, differentiated capabilities, global foo

    2/3/26 4:10:00 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    $MMM
    SEC Filings

    View All

    3M Company filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - 3M CO (0000066740) (Filer)

    2/5/26 8:32:39 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    SEC Form S-3ASR filed by 3M Company

    S-3ASR - 3M CO (0000066740) (Filer)

    2/3/26 4:50:35 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    SEC Form IRANNOTICE filed by 3M Company

    IRANNOTICE - 3M CO (0000066740) (Filer)

    2/3/26 4:15:06 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    $MMM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    3M downgraded by Analyst with a new price target

    Analyst downgraded 3M from Overweight to Neutral and set a new price target of $182.00

    1/16/26 8:27:24 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    3M downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded 3M from Buy to Hold and set a new price target of $178.00

    12/8/25 8:20:58 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    3M upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded 3M from Underweight to Equal-Weight and set a new price target of $160.00

    10/22/25 6:59:04 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    $MMM
    Financials

    Live finance-specific insights

    View All

    3M Board Declares Quarterly Dividend

    ST. PAUL, Minn., Feb. 3, 2026 /PRNewswire/ -- The 3M Company Board of Directors (NYSE:MMM) today declared a dividend on the company's common stock of $0.78 per share for the first quarter of 2026. The dividend is payable March 12, 2026, to shareholders of record at the close of business on Feb. 13, 2026. 3M has paid dividends to its shareholders without interruption for more than 100 years. About 3M 3M (NYSE:MMM) is focused on transforming industries around the world by applying science and creating innovative, customer-focused solutions. Our multi-disciplinary team is working to solve tough customer problems by leveraging diverse technology platforms, differentiated capabilities, global foo

    2/3/26 4:10:00 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    3M Reports Fourth-Quarter and Full-Year 2025 Results; Initiates Full-Year 2026 Financial Guidance

    Q4 GAAP sales of $6.1 billion, up 2.1%; operating margin of 13.0%, down 510 bps; EPS of $1.07, down 20%, all YoYAdjusted sales of $6.0 billion with organic growth of 2.2% YoYAdjusted operating margin of 21.1%, up 140 bps YoYAdjusted EPS of $1.83, up 9% YoYQ4 operating cash flow of $1.6 billion with adjusted free cash flow of $1.3 billionFull-year GAAP sales of $24.9 billion, up 1.5%; operating margin of 18.6%, down 100 bps; EPS of $6.00, down 17%, all YoYAdjusted sales of $24.3 billion with organic growth of 2.1% YoYAdjusted operating margin of 23.4%, up 200 bps YoYAdjusted EPS of $8.06, up 10% YoYFull-year operating cash flow of $2.3 billion with adjusted free cash flow of $4.4 billionST. P

    1/20/26 6:30:00 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    3M Announces Upcoming Investor Event

    ST. PAUL, Minn., Jan. 6, 2026 /PRNewswire/ -- 3M (NYSE:MMM) today announced the following investor event: Fourth-quarter 2025 earnings conference call on Tuesday, Jan. 20, 2026, at 8 a.m. CT.This event will be webcast live and a replay will be available on 3M's Investor Relations website at http://investors.3M.com. About 3M3M (NYSE:MMM) is focused on transforming industries around the world by applying science and creating innovative, customer-focused solutions. Our multi-disciplinary team is working to solve tough customer problems by leveraging diverse technology platforms, differentiated capabilities, global footprint, and operational excellence. Discover how 3M is shaping the future at 3

    1/6/26 10:15:00 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    $MMM
    Leadership Updates

    Live Leadership Updates

    View All

    3M appoints Meagan Linn as Senior Vice President, Government Affairs

    ST. PAUL, Minn., Feb. 16, 2026 /PRNewswire/ -- 3M today announced the appointment of Meagan Linn as Senior Vice President, Government Affairs. In this role, Linn will oversee the company's engagement with the executive branch, policymakers, regulatory agencies, and industry associations, globally to advance public policy dialogue. She will also be responsible for developing business growth through government contracts. Linn brings 20 years of experience in public policy, with 12 years at Northrop Grumman Corporation, most recently as government policy lead and Chief of Staff, an

    2/16/26 10:00:00 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    Lanvin Group Announces Appointment of New Chief Financial Officer

    SHANGHAI, Oct. 24, 2025 /PRNewswire/ -- Lanvin Group (NYSE:LANV), a global luxury fashion group, today announced the appointment of Mr. Jiyang Han as Chief Financial Officer (CFO) of the Company, effective November 1, 2025. In this role, Mr. Han will oversee the Group's financial affairs, including financial planning and analysis, accounting and controllership, financial management, treasury, investment and financing projects, and investor relations.  Mr. Han brings nearly two decades of experience in corporate finance, investment banking, and global business management. He has served as Co-CIO and Assistant President of Yuyuan (SHSE: 600655) since June 2025. Prior to that, he was the M&A a

    10/24/25 6:00:00 AM ET
    $LANV
    $MMM
    Apparel
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    3M Annual Meeting Results

    ST. PAUL, Minn., May 13, 2025 /PRNewswire/ -- At today's Annual Meeting of Shareholders, 3M (NYSE:MMM) shareholders overwhelmingly supported each of the proposals recommended for approval by the company. Preliminary Shareholder Voting Results 3M shareholders today voted on the following business items: 1) Shareholders supported 11 directors for one-year terms to expire at the company's 2026 Annual Meeting: David P. Bozeman, President, Chief Executive Officer and Director, C.H. Robinson Worldwide, Inc.Thomas "Tony" K. Brown, retired Group Vice President, Global Purchasing, Ford

    5/13/25 4:30:00 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    $MMM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by 3M Company (Amendment)

    SC 13G/A - 3M CO (0000066740) (Subject)

    2/13/24 4:56:03 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by 3M Company (Amendment)

    SC 13G/A - 3M CO (0000066740) (Subject)

    2/9/23 10:54:46 AM ET
    $MMM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by 3M Company (Amendment)

    SC 13G/A - 3M CO (0000066740) (Subject)

    2/9/22 3:15:56 PM ET
    $MMM
    Medical/Dental Instruments
    Health Care